Display options
Cite
Ribeil JA. Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?. Am J Hematol. 2021;doi: 10.1002/ajh.26371.
Ribeil, J. A. (2021). Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?. American journal of hematology, . https://doi.org/10.1002/ajh.26371
Ribeil, Jean-Antoine. "Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?." American journal of hematology vol. (2021). doi: https://doi.org/10.1002/ajh.26371
Ribeil JA. Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?. Am J Hematol. 2021 Oct 09; doi: 10.1002/ajh.26371. Epub 2021 Oct 09. PMID: 34626435.
Copy Download .nbib Format: NLM
Share it on

Am J Hematol. 2021 Oct 09; doi: 10.1002/ajh.26371. Epub 2021 Oct 09.

Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?.

American journal of hematology

Jean-Antoine Ribeil

Affiliations

  1. Section of Hematology/Oncology, Boston University and Boston Medical Center; Sickle Cell Center, Boston University School of Medicine, Boston, Massachusetts, USA.

PMID: 34626435 DOI: 10.1002/ajh.26371

[No abstract available.]

References

  1. Green SE, Singh ZN, Baer MR. Primary myelofibrosis in a patient with sickle cell disease. Am J Hematol. 2021;1-2. doi:10.1002/ajh.26347 - PubMed
  2. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003;74:249-253. doi:10.1002/ajh.10427 - PubMed
  3. Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130:1597-1599. doi:10.1182/blood-2017-05-783233 - PubMed
  4. Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ. Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J R Soc Med. 2016;109:303-309. doi:10.1177/0141076816651037 - PubMed
  5. Li Y, Maule J, Neff JL, et al. Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod Pathol. 2019;32:1712-1726. doi:10.1038/s41379-019-0325-6 - PubMed
  6. Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128:110-116. doi:10.1177/003335491312800206 - PubMed
  7. Adelman ER, Figueroa ME. Human hematopoiesis: aging and leukemogenic risk. Curr Opin Hematol. 2021;28:57-63. doi:10.1097/MOH.0000000000000622 - PubMed
  8. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85:403-408. doi:10.1002/ajh.21699 - PubMed
  9. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939-955. doi:10.7326/0003-4819-148-12-200806170-00221 - PubMed
  10. Tolu SS, Wang K, Yan Z, et al. Characterization of hematopoiesis in sickle cell disease by prospective isolation of stem and progenitor cells. Cells. 2020;9:E2159. doi:10.3390/cells9102159 - PubMed
  11. bluebird bio announces temporary suspension on phase 1/2 and phase 3 studies of LentiGlobin gene therapy for sickle cell disease (bb1111). 2021. Accessed September 28, 2021. https://www.businesswire.com/news/home/20210216005442/en/bluebird-bio-Announces-Temporary-Suspension-on-Phase-12-and-Phase-3-Studies-of-LentiGlobin-Gene-Therapy-for-Sickle-Cell-Disease-bb1111 - PubMed
  12. Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138:942-947. doi:10.1182/blood.2021011488 - PubMed
  13. Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4:2058-2063. doi:10.1182/bloodadvances.2019001330 - PubMed
  14. bluebird bio provides updated findings from reported case of acute myeloid leukemia (AML) in LentiGlobin for sickle cell disease (SCD) gene therapy program. 2021. Accessed September 28, 2021. https://www.businesswire.com/news/home/20210310005286/en/bluebird-bio-Provides-Updated-Findings-from-Reported-Case-of-Acute-Myeloid-Leukemia-AML-in-LentiGlobin-for-Sickle-Cell-Disease-SCD-Gene-Therapy-Program - PubMed
  15. Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;6:e585-e596. doi:10.1016/S2352-3026(19)30154-1 - PubMed
  16. Ghannam JY, Xu X, Maric I, et al. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood. 2020;135:1185-1188. doi:10.1182/blood.2019004001 - PubMed
  17. Bernaudin F, Dalle J-H, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105:91-101. doi:10.3324/haematol.2018.213207 - PubMed
  18. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43-52. doi:10.1182/blood-2002-11-3343 - PubMed
  19. Snetsinger B, Ferrone CK, Rauh MJ. Targeted, amplicon-based, next-generation sequencing to detect age-related clonal hematopoiesis. Methods Mol Biol. 2019;2045:167-180. doi:10.1007/7651_2019_216 - PubMed
  20. El Hoss S, Cochet S, Godard A, et al. Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease. Haematologica. 2020;106:2707-2719. doi:10.3324/haematol.2020.265462 - PubMed
  21. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338. doi:10.1172/JCI10726 - PubMed
  22. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies. Mol Cancer Res. 2014;12:1347-1354. doi:10.1158/1541-7786.MCR-14-0028 - PubMed
  23. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129-151. - PubMed
  24. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;97:1180-1195. doi:10.1182/blood.V97.5.1180 - PubMed
  25. Bernaudin F T, Kuentz M, Beuzard Y. Drépanocytose et risque d'hémopathies malignes. Hématologie. 2021;27:173-187. doi:10.1684/hma.2021.1660 - PubMed
  26. Liggett LA, Cato LD, Weinstock JS, et al. Clonal hematopoiesis in sickle cell disease. 2021. 2021.06.12.21258772. doi:10.1101/2021.06.12.21258772 - PubMed
  27. Pincez T, Lee SSK, Ilboudo Y, et al. Clonal hematopoiesis in sickle cell disease. Blood. 2021. doi:10.1182/blood.2021011121 - PubMed

Publication Types